These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12057613)

  • 1. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid.
    Torii Y; Tokumaru Y; Kawaguchi S; Izumi N; Maruyama S; Mukamoto M; Kozaki S; Takahashi M
    Vaccine; 2002 Jun; 20(19-20):2556-61. PubMed ID: 12057613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan.
    Torii Y; Sugimoto N; Kohda T; Kozaki S; Morokuma K; Horikawa Y; Ginnaga A; Yamamoto A; Takahashi M
    Jpn J Infect Dis; 2017 Jul; 70(4):423-429. PubMed ID: 28250257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.
    Pittman PR; Hack D; Mangiafico J; Gibbs P; McKee KT; Friedlander AM; Sjogren MH
    Vaccine; 2002 May; 20(16):2107-15. PubMed ID: 11972980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM; Motter RN; Arnon SS
    Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.
    Held DM; Shurtleff AC; Fields S; Green C; Fong J; Jones RG; Sesardic D; Buelow R; Burke RL
    Clin Vaccine Immunol; 2010 Jun; 17(6):930-6. PubMed ID: 20410329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid.
    Siegel LS
    J Clin Microbiol; 1989 Aug; 27(8):1906-8. PubMed ID: 2768475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay.
    Siegel LS
    J Clin Microbiol; 1988 Nov; 26(11):2351-6. PubMed ID: 3235662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows.
    Krüger M; Skau M; Shehata AA; Schrödl W
    Anaerobe; 2013 Oct; 23():97-101. PubMed ID: 23831724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative vaccination against equine botulism (BoNT/C).
    Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R
    Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of botulinum C/D mosaic toxoid against avian botulism.
    Takeda M; Kasai H; Torii Y; Mukamoto M; Kohda T; Tsukamoto K; Kozaki S
    J Vet Med Sci; 2006 Apr; 68(4):325-30. PubMed ID: 16679722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
    Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
    Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of new formalin-detoxified botulinum neurotoxin toxoids.
    Keller JE
    Clin Vaccine Immunol; 2008 Sep; 15(9):1374-9. PubMed ID: 18667637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Clostridium botulinum type C antitoxin titers in mink and guinea pigs to protection against type C intoxication in mink.
    Kolbe DR; Coe Clough NE
    Anaerobe; 2008 Apr; 14(2):128-30. PubMed ID: 18032073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics study of immunological response to Clostridium botulinum toxin.
    Dezfulian M; Bitar RA; Bartlett JG
    J Clin Microbiol; 1987 Jul; 25(7):1336-7. PubMed ID: 3301895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved method for development of toxoid vaccines and antitoxins.
    Jones RG; Liu Y; Rigsby P; Sesardic D
    J Immunol Methods; 2008 Aug; 337(1):42-8. PubMed ID: 18571196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D.
    Stahl C; Unger L; Mazuet C; Popoff M; Straub R; Frey J
    Vaccine; 2009 Sep; 27(41):5661-6. PubMed ID: 19646409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, measurement and possible use of human antitoxin against Cl. botulinum A, B, and E toxins.
    Habermann E; Bernáth S
    Med Microbiol Immunol; 1975 Jul; 161(3):203-10. PubMed ID: 1237779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Guo JP; An HJ; Zhang SM; Wang S; Yu WY; Sun ZW
    Vaccine; 2013 May; 31(20):2427-32. PubMed ID: 23583890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New equine antitoxins to botulinum neurotoxins serotypes A and B.
    Li D; Mattoo P; Keller JE
    Biologicals; 2012 Jul; 40(4):240-6. PubMed ID: 22560800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.